Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany-Reference-Cited by-同舟云学术

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

Published:2020-12 Issue: Volume:54 Page:88-95
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Schneeweiss Andreas,Ettl Johannes,Lüftner Diana,Beckmann Matthias W.,Belleville Erik,Fasching Peter A.,Fehm Tanja N.,Geberth Matthias,Häberle Lothar,Hadji Peyman,Hartkopf Andreas D.,Hielscher Carsten,Huober Jens,Ruckhäberle Eugen,Janni Wolfgang,Kolberg Hans Christian,Kurbacher Christian M.,Klein Evelyn,Lux Michael P.,Müller Volkmar,Nabieva Naiba,Overkamp Friedrich,Tesch Hans,Laakmann Elena,Taran Florin-Andrei,Seitz Julia,Thomssen Christoph,Untch Michael,Wimberger Pauline,Wuerstlein Rachel,Volz Bernhard,Wallwiener Diethelm,Wallwiener Markus,Brucker Sara Y.

Funder

Pfizer

Roche

Eisai

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference23 articles.

1. Translational highlights in breast cancer research and treatment: recent developments with clinical impact;Fasching;Curr Opin Obstet Gynecol,2019

2. Overall survival with ribociclib plus endocrine therapy in breast cancer;Im;N Engl J Med,2019

3. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial;Sledge;JAMA Oncol,2019

4. Overall survival results from the phase 3 MONALEESA-3 study of fulvestrant ± ribociclib in postmenopausal patients with HR+/HER2− advanced breast cancer;Slamon;Ann Oncol,2019

5. Overall survival with palbociclib and fulvestrant in advanced breast cancer;Turner;N Engl J Med,2018

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Data with CDK4/6 Inhibitors—A Single Center Experience from Croatia;Journal of Personalized Medicine;2024-08-23

2. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-05-29

3. Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-05-23

4. Real-world effectiveness of CDK4/6 inhibitors on patients with HR+/HER2– advanced breast cancer in South Korea, focusing on underrepresented patients;Current Medical Research and Opinion;2024-05-09

5. Real-World Data Analysis of CDK4/6 Inhibitor Therapy—A Patient-Centric Single Center Study;Cancers;2024-05-01